Background Sub-Saharan Africa (SSA) population is genetically diverse and heterogenous
thus variability in drug response among individuals is predicted to be high. Cytochrome …

Background The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …

Abstract Background Cytochrome P450 (CYP) enzymes are essential in the metabolism of
most drugs used today. Single nucleotide polymorphism (s) occurring in CYP genes can …

The human Cytochrome (cyp2C8) and N-acetyltransferase II (nat2) genes may vary between
individuals resulting in differences in anti-plasmodial treatment responses. We set out in this …

Background Artemisinin-based combinations currently recommended for treatment of
uncomplicated Plasmodium falciparum malaria in many countries of sub-Saharan Africa are …

The pharmacogenetics of antimalarial agents are poorly known, although the application of
pharmacogenetics might be critical in optimizing treatment. This population pharmacokinetic …

Malaria remains a disease of major public health concern globally, with endemicity more
pronounced in the sub-Saharan Africa while children below the age of five alongside …

Malaria constitutes a major public health concern in tropical and other malaria-endemic
regions. Genetic and non-genetic factors are known to in uence the pharmacokinetics and/or …

Abstract Objective Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of
artemisinin drugs, a novel series of antimalarials. Our aim was to analyze the prevalence of …

Malaria is a major infectious disease. In the last 10 years it has killed more than 20 million
people, mainly small children in Africa. The highly efficacious artemisinine combination …